Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
38
TGTX Quote, Financials, Valuation and Earnings
Last price:
$29.42
Seasonality move
:
5.12%
Day range:
$29.09 - $29.99
52-week range:
$25.28 - $46.48
Dividend yield:
0%
P/E ratio:
10.59x
P/S ratio:
7.70x
P/B ratio:
7.20x
Volume:
1.6M
Avg. volume:
1.3M
1-year change:
-2.29%
Market cap:
$4.7B
Revenue:
$616.3M
EPS (TTM):
$2.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$193.3M | $0.33 | 65.01% | 1061.06% | $44.43 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 31.89% | 267.32% | $14.50 |
|
GERN
Geron Corp.
|
$50.4M | -$0.05 | 26.52% | -32.89% | $3.40 |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$141.8M | $0.06 | 33.34% | -31.02% | $122.36 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 36.67% | -59.34% | $7.72 |
|
RCUS
Arcus Biosciences, Inc.
|
$24.9M | -$1.08 | -34.01% | -24.44% | $33.70 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$29.40 | $44.43 | $4.7B | 10.59x | $0.00 | 0% | 7.70x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.36 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.02x |
|
GERN
Geron Corp.
|
$1.55 | $3.40 | $989.5M | -- | $0.00 | 0% | 5.62x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$90.09 | $122.36 | $4.6B | -- | $0.00 | 0% | 8.95x |
|
MNKD
MannKind Corp.
|
$3.04 | $7.72 | $932M | 180.65x | $0.00 | 0% | 2.72x |
|
RCUS
Arcus Biosciences, Inc.
|
$23.94 | $33.70 | $3B | -- | $0.00 | 0% | 10.42x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
28.14% | -2.844 | 5.36% | 2.91x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -0.359 | 9.99% | 1.72x |
|
GERN
Geron Corp.
|
-- | 0.298 | -- | 3.16x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
50.38% | 1.423 | 7.87% | 2.46x |
|
MNKD
MannKind Corp.
|
112.08% | 0.597 | 27.19% | 1.23x |
|
RCUS
Arcus Biosciences, Inc.
|
23.88% | 2.455 | 6.72% | 4.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$154.4M | $50.5M | 68.59% | 112.28% | 26.22% | $19.6M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
GERN
Geron Corp.
|
$46.7M | -$10.8M | -18.85% | -33.5% | -22.47% | -$13.5M |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$120.6M | -$4.6M | -4.01% | -8.84% | -3.07% | $5.5M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
|
RCUS
Arcus Biosciences, Inc.
|
$30M | -$114M | -53.99% | -67.06% | -345.46% | -$121M |
TG Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TGTX or FOLD?
Amicus Therapeutics, Inc. has a net margin of 11.96% compared to TG Therapeutics, Inc.'s net margin of 0.91%. TG Therapeutics, Inc.'s return on equity of 112.28% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.80.16% $0.14 $901.7M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About TGTX or FOLD?
TG Therapeutics, Inc. has a consensus price target of $44.43, signalling upside risk potential of 51.12%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.98%. Given that TG Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is TGTX or FOLD More Risky?
TG Therapeutics, Inc. has a beta of 1.867, which suggesting that the stock is 86.685% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.430, suggesting its less volatile than the S&P 500 by 56.973%.
-
Which is a Better Dividend Stock TGTX or FOLD?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or FOLD?
TG Therapeutics, Inc. quarterly revenues are $192.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. TG Therapeutics, Inc.'s net income of $23M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 7.70x versus 7.02x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.7.70x 10.59x $192.6M $23M FOLDAmicus Therapeutics, Inc.7.02x -- $185.2M $1.7M
-
Which has Higher Returns TGTX or GERN?
Geron Corp. has a net margin of 11.96% compared to TG Therapeutics, Inc.'s net margin of -64.86%. TG Therapeutics, Inc.'s return on equity of 112.28% beat Geron Corp.'s return on equity of -33.5%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.80.16% $0.14 $901.7M GERNGeron Corp.97.28% -$0.05 $223.6M -
What do Analysts Say About TGTX or GERN?
TG Therapeutics, Inc. has a consensus price target of $44.43, signalling upside risk potential of 51.12%. On the other hand Geron Corp. has an analysts' consensus of $3.40 which suggests that it could grow by 119.36%. Given that Geron Corp. has higher upside potential than TG Therapeutics, Inc., analysts believe Geron Corp. is more attractive than TG Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 GERNGeron Corp.3 1 1 -
Is TGTX or GERN More Risky?
TG Therapeutics, Inc. has a beta of 1.867, which suggesting that the stock is 86.685% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.581, suggesting its less volatile than the S&P 500 by 41.892%.
-
Which is a Better Dividend Stock TGTX or GERN?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or GERN?
TG Therapeutics, Inc. quarterly revenues are $192.6M, which are larger than Geron Corp. quarterly revenues of $48M. TG Therapeutics, Inc.'s net income of $23M is higher than Geron Corp.'s net income of -$31.1M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 7.70x versus 5.62x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.7.70x 10.59x $192.6M $23M GERNGeron Corp.5.62x -- $48M -$31.1M
-
Which has Higher Returns TGTX or MIRM?
Mirum Pharmaceuticals, Inc. has a net margin of 11.96% compared to TG Therapeutics, Inc.'s net margin of -3.85%. TG Therapeutics, Inc.'s return on equity of 112.28% beat Mirum Pharmaceuticals, Inc.'s return on equity of -8.84%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.80.16% $0.14 $901.7M MIRMMirum Pharmaceuticals, Inc.80.97% -$0.11 $634.1M -
What do Analysts Say About TGTX or MIRM?
TG Therapeutics, Inc. has a consensus price target of $44.43, signalling upside risk potential of 51.12%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $122.36 which suggests that it could grow by 35.82%. Given that TG Therapeutics, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Mirum Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 MIRMMirum Pharmaceuticals, Inc.7 0 0 -
Is TGTX or MIRM More Risky?
TG Therapeutics, Inc. has a beta of 1.867, which suggesting that the stock is 86.685% more volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.520, suggesting its less volatile than the S&P 500 by 48.002%.
-
Which is a Better Dividend Stock TGTX or MIRM?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or MIRM?
TG Therapeutics, Inc. quarterly revenues are $192.6M, which are larger than Mirum Pharmaceuticals, Inc. quarterly revenues of $148.9M. TG Therapeutics, Inc.'s net income of $23M is higher than Mirum Pharmaceuticals, Inc.'s net income of -$5.7M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 7.70x versus 8.95x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.7.70x 10.59x $192.6M $23M MIRMMirum Pharmaceuticals, Inc.8.95x -- $148.9M -$5.7M
-
Which has Higher Returns TGTX or MNKD?
MannKind Corp. has a net margin of 11.96% compared to TG Therapeutics, Inc.'s net margin of -14.25%. TG Therapeutics, Inc.'s return on equity of 112.28% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.80.16% $0.14 $901.7M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About TGTX or MNKD?
TG Therapeutics, Inc. has a consensus price target of $44.43, signalling upside risk potential of 51.12%. On the other hand MannKind Corp. has an analysts' consensus of $7.72 which suggests that it could grow by 154.44%. Given that MannKind Corp. has higher upside potential than TG Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than TG Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 MNKDMannKind Corp.8 1 0 -
Is TGTX or MNKD More Risky?
TG Therapeutics, Inc. has a beta of 1.867, which suggesting that the stock is 86.685% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.
-
Which is a Better Dividend Stock TGTX or MNKD?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or MNKD?
TG Therapeutics, Inc. quarterly revenues are $192.6M, which are larger than MannKind Corp. quarterly revenues of $112M. TG Therapeutics, Inc.'s net income of $23M is higher than MannKind Corp.'s net income of -$15.9M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while MannKind Corp.'s PE ratio is 180.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 7.70x versus 2.72x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.7.70x 10.59x $192.6M $23M MNKDMannKind Corp.2.72x 180.65x $112M -$15.9M
-
Which has Higher Returns TGTX or RCUS?
Arcus Biosciences, Inc. has a net margin of 11.96% compared to TG Therapeutics, Inc.'s net margin of -321.21%. TG Therapeutics, Inc.'s return on equity of 112.28% beat Arcus Biosciences, Inc.'s return on equity of -67.06%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.80.16% $0.14 $901.7M RCUSArcus Biosciences, Inc.90.91% -$0.89 $829M -
What do Analysts Say About TGTX or RCUS?
TG Therapeutics, Inc. has a consensus price target of $44.43, signalling upside risk potential of 51.12%. On the other hand Arcus Biosciences, Inc. has an analysts' consensus of $33.70 which suggests that it could grow by 40.77%. Given that TG Therapeutics, Inc. has higher upside potential than Arcus Biosciences, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Arcus Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 RCUSArcus Biosciences, Inc.9 3 0 -
Is TGTX or RCUS More Risky?
TG Therapeutics, Inc. has a beta of 1.867, which suggesting that the stock is 86.685% more volatile than S&P 500. In comparison Arcus Biosciences, Inc. has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.303%.
-
Which is a Better Dividend Stock TGTX or RCUS?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcus Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Arcus Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or RCUS?
TG Therapeutics, Inc. quarterly revenues are $192.6M, which are larger than Arcus Biosciences, Inc. quarterly revenues of $33M. TG Therapeutics, Inc.'s net income of $23M is higher than Arcus Biosciences, Inc.'s net income of -$106M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Arcus Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 7.70x versus 10.42x for Arcus Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.7.70x 10.59x $192.6M $23M RCUSArcus Biosciences, Inc.10.42x -- $33M -$106M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is up 22.11% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 20.87% over the past day.
